Figure 6.

Proposed molecular basis for SCD1 ASO-mediated metabolic effects in mice. SCD1 ASOs directly reduce SCD1 levels in liver. SCD1 ASOs also reduce SCD1 in WAT and BAT; however, whether the reduction is due to direct or indirect effects remains unknown and is indicated by question marks. In liver, the reduction of SCD1 leads to increased CPT1 levels first and decreased SREBP-1, FAS, ACC1, and ACC2 later. It is possible that the downregulation of FAS, ACC1, and ACC2 may be downstream of the transcription factor SREBP-1. In WAT, reduction of SCD1 leads to reduction of FAS. In BAT, reduction of SCD1 leads to increase in UCP2 first and then UCP1, UCP3, and β3-AR.